Hyperactivating mutations such as BRAF V600E and BRAF–KIAA1549 fusions are frequently observed in pediatric and adult low-grade gliomas, such as PAs, gangliogliomas, and PXAs [54,148]. Here, BRAF is linked to central nervous system cancer.